The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Big Pharma vs. Big Pharma in Court Battles over Biosimilar Drugs

Big Pharma vs. Big Pharma in Court Battles over Biosimilar Drugs

October 4, 2016 • By John Miller

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ZURICH (Reuters)—The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines.

You Might Also Like
  • Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles
  • U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight

These drug makers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars—biopharmaceutical drugs with the treatment properties of medicines they seek to mimic—while simultaneously challenging rivals’ patent claims.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics.

The allure of biosimilars is clear, with insurers and other payers counting on the steep discounts. U.S. pharmacy benefit managers are already trimming brand-name drugs from their rosters.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

With Novartis Chief Executive Joe Jimenez predicting biosimilar discounts of up to 75%, in part based on developments in Europe, makers of innovative drugs are fighting tooth and nail to protect their higher-priced products for as long as possible.

For instance, AbbVie has sued in Delaware claiming patent protection for its arthritis drug, adalimumab (Humira), the world’s best-selling prescription medicine, until at least 2022 as it seeks to delay an Amgen replica that won U.S. approval last week.

Meanwhile, Amgen has gone to another U.S. federal court seeking to protect its own arthritis medicine, etanercept (Enbrel), from a Novartis biosimilar until 2029.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

With lawsuits pitting Big Pharma against Big Pharma piling up, lawyers said the legal landscape has gotten a lot more complex.

“One of the biggest surprises has been the number of innovator biopharma companies, like Amgen, now developing biosimilars to compete with the products of other innovator companies,” says Don Ware, an expert on biosimilars at U.S. law firm Foley Hoag in Boston.

“This creates conflicts for law firms like ours, because suddenly the clients we advise are adverse to each other,” Ware said. “And it makes it hard for the companies to retain top outside counsel without having to give them conflict waivers.”

Sanofi, Merck, Eli Lilly, Pfizer, Johnson & Johnson and Biogen are also embroiled in lawsuits over biosimilars.

Not Bitter Enemies
Even so, some analysts say the lawsuits are business as usual and are unlikely to spill over into other areas, including research partnerships.

Novartis and Amgen may be at each other’s throats in court over the Swiss drug maker’s etanercept copy, but the two are still cooperating on a drug for migraines.

“It’s not like these companies are bitter enemies,” Zuercher Kantonalbank analyst Michael Nawrath says. “These court cases are simply the last resort of original drug makers to wring a few more months or a year of exclusivity from their blockbusters.”

Conflicts pitting big drug makers against each other may have been inevitable after Europe in 2006 and the United States in 2010 created separate biosimilar approval rules.

After all, Big Pharma’s financial clout and expertise made large, sophisticated drug makers the natural candidates to manufacture complex biosimilar copies that cost hundreds of millions to bring to market, far more than for generic off-patent copies of simpler, small molecule drugs.

Some smaller companies and generics makers have jettisoned biosimilar programs after originally underestimating hurdles to entry, Richard Francis, head of Novartis’s Sandoz division that makes biosimilars, said earlier this year.

Just this week, Shire abandoned two biosimilar candidate drugs that accompanied its Baxalta takeover, copies of Amgen’s Enbrel and AbbVie’s Humira (adalimumab), to focus on rare diseases.

“The realisation of what it’s going to take to stay in this market and be successful has led to a change in the landscape and the players in it,” Francis says.

Pages: 1 2 | Multi-Page

Filed Under: Biologics & Biosimilars, Drug Updates, Legal Tagged With: AbbVie, adalimumab, adalimumab-atto, Amgen, Biosimilars, etanercept, etanercept-szzs, lawsuit, Legal, Novartis

You Might Also Like:
  • Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles
  • U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales
  • U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight
  • U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.